Sorry, you need to enable JavaScript to visit this website.

Antipsychotic dose mediates the association between polypharmacy and corrected QT interval

TitoloAntipsychotic dose mediates the association between polypharmacy and corrected QT interval
Tipo di pubblicazioneArticolo su Rivista peer-reviewed
Anno di Pubblicazione2016
AutoriBarbui, C., Bighelli I., Carrà G., Castellazzi M., Lucii C., Martinotti G., Nosè M., Ostuzzi G., Acciavatti T., Adamo A., et al.
RivistaPLoS ONE
Volume11
ISSN19326203
Parole chiaveadult, aged, antidepressant agent, aripiprazole, article, clinical practice, clozapine, controlled study, cross-sectional study, disease association, Female, haloperidol, heart rate, human, Italy, major clinical study, male, mental disease, monotherapy, mood stabilizer, neuroleptic agent, olanzapine, paliperidone, polypharmacy, QT interval, QT prolongation, quetiapine, risk factor, risperidone
Abstract

{Antipsychotic (AP) drugs have the potential to cause prolongation of the QT interval corrected for heart rate (QTc). As this risk is dose-dependent, it may be associated with the number of AP drugs concurrently prescribed, which is known to be associated with increased cumulative equivalent AP dosage. This study analysed whether AP dose mediates the relationship between polypharmacy and QTc interval. We used data from a crosssectional survey that investigated the prevalence of QTc lengthening among people with psychiatric illnesses in Italy. AP polypharmacy was tested for evidence of association with AP dose and QTc interval using the Baron and Kenny mediational model. A total of 725 patients were included in this analysis. Of these, 186 (26%) were treated with two or more AP drugs (AP polypharmacy). The mean cumulative AP dose was significantly higher in those receiving AP polypharmacy (prescribed daily dose/defined daily dose = 2.93, standard deviation 1.31) than monotherapy (prescribed daily dose/defined daily dose = 0.82, standard deviation 0.77) (z = -12.62, p < 0.001). Similarly, the mean QTc interval was significantly longer in those receiving AP polypharmacy (mean = 420.86 milliseconds, standard deviation 27.16) than monotherapy (mean = 413.42 milliseconds, standard deviation 31.54) (z = -2.70

Note

cited By 4

URLhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84978025201&doi=10.1371%2fjournal.pone.0148212&partnerID=40&md5=7e7d4c86fe6b297c39c4127234fe7926
DOI10.1371/journal.pone.0148212
Citation KeyBarbui2016